(Q44018391)

29 November 2017

Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates (English)

1 reference

29 November 2017

0 references

1 reference

16

1 reference

Severine Chevalley-Maurel

29 November 2017

6

Geert-Jan van Gemert

0 references

7

Severine Chevalley-Maurel

0 references

Blandine Franke-Fayard

8

Blandine M D Franke-Fayard

0 references

Jean-François Franetich

11

Jean-Francois Franetich

0 references

Chris J Janse

Chris J Janse

14

0 references

Robert W Sauerwein

15

Robert W Sauerwein

1 reference

29 November 2017

13

Stephen L Hoffman

1 reference

29 November 2017

2

Ivo H J Ploemen

1 reference

29 November 2017

9

Cornelus C Hermsen

1 reference

29 November 2017

1

Takeshi Annoura

1 reference

29 November 2017

3

Ben C L van Schaijk

1 reference

29 November 2017

5

Martijn W Vos

1 reference

29 November 2017

10

Audrey Gego

1 reference

29 November 2017

12

Dominique Mazier

1 reference

29 November 2017

Mohammed Sajid

4

1 reference

29 November 2017

Severine Chevalley-Maurel

7

1 reference

29 November 2017

Jean-Francois Franetich

11

1 reference

29 November 2017

language of work or name

English

0 references

publication date

16 February 2012

1 reference

29 November 2017

1 reference

29 November 2017

30

1 reference

29 November 2017

16

1 reference

29 November 2017

2662-2670

1 reference

Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

That Was Then But This Is Now: Malaria Research in the Time of an Eradication Agenda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Malaria vaccines: the case for a whole-organism approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically modified Plasmodium parasites as a protective experimental malaria vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Conserved protective mechanisms in radiation and genetically attenuated uis3(-) and uis4(-) Plasmodium sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Priming of CD8+ T cell responses following immunization with heat-killed Plasmodium sporozoites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Plasmodium berghei: production and quantitation of hepatic stages derived from irradiated sporozoites in rats and mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically engineered, attenuated whole-cell vaccine approaches for malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Type II fatty acid synthesis is essential only for malaria parasite late liver stage development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Genetically attenuated P36p-deficient Plasmodium berghei sporozoites confer long-lasting and partial cross-species protection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Redefining the role of de novo fatty acid synthesis in Plasmodium parasites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Structural models for the protein family characterized by gamete surface protein Pfs230 of Plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Three members of the 6-cys protein family of Plasmodium play a role in gamete fertility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Two proteins with 6-cys motifs are required for malarial parasites to commit to infection of the hepatocyte

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Beta-ketoacyl-ACP synthase I/II from Plasmodium falciparum (PfFabB/F)--is it B or F?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

The Fatty Acid Biosynthesis Enzyme FabI Plays a Key Role in the Development of Liver-Stage Malarial Parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.02.010

10.1016/J.VACCINE.2012.02.010

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference